Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience
Authors' conclusion
Pasireotide provided clinical benefit and was well tolerated for more than 11 years of treatment in acromegaly patients, most of whom were resistant to first-generation SRLs.
Study context
- Population
- Patients with acromegaly from a primary care center enrolled in clinical studies with pasireotide (first visit November 2008; data cutoff June 2022)30 continued in rollover
- Participants
- 50 patients
- Outcome
- Safety and biochemical control (age-adjusted IGF-1 ≤ upper limit of normal)
Methodological detailssingle-centre, real-world, prospectively maintained database, 27 still receiving pasireotide at data cutoff (June 2022)
- Single-centre
- Real-world
- Prospectively maintained database
- 27 still receiving pasireotide at data cutoff (June 2022)
Main finding
As reported in the abstract
Biochemical control: normal IGF-1 (age-adjusted IGF-1 ≤ upper limit of normal)
Normal IGF-1 achieved
54%
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Tumor volume reduction | Pasireotide 63% |
- Tumor volume reduction: evaluable patients (n = 10/16)
Symptoms and quality of life
- Acromegaly symptoms and quality of life improved with treatment
Predictors of response
- No predictors of pasireotide response identified; controlled patients had smaller tumors and lower growth hormone (GH) at baseline
Safety
- Hyperglycemic events in patients with normal glucose before treatment
- 63.2%
- Most patients presented hyperglycemic events
- Older patients and those with higher IGF-1, glucose and HbA1c at baseline had higher glucose and HbA1c during treatment
Original publication
Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience. J Clin Endocrinol Metab. Published 26 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →